By WSJ Staff
Shares in Moderna tumbled after the vaccine maker gave a revenue forecast for this year that fell far short of expectations, and said it would cut $1 billion of costs in 2025.
-- Shares recently traded at $33.14, down nearly 22%.
-- That put the stock on course for its lowest close since April 13, 2020, according to Dow Jones Market Data.
-- Such a fall would be largest percent decrease since the biotech company went public in December 2018.
Moderna said Monday it expects to bring in between $1.5 billion and $2.5 billion of revenue in 2025. Analysts polled by FactSet had expected revenue of about $2.92 billion.
The drug maker's financial update came as health sector leaders gathered for an annual industry conference. Read more:
This item is part of a Wall Street Journal live coverage event. The full stream can be found by searching P/WSJL (WSJ Live Coverage).
(END) Dow Jones Newswires
January 13, 2025 11:02 ET (16:02 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.